This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maache, M.
Right arrow Articles by Paranhos-Baccalà, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maache, M.
Right arrow Articles by Paranhos-Baccalà, G.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, March 2006, p. 409-414, Vol. 13, No. 3
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.3.409-414.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

False-Positive Results in a Recombinant Severe Acute Respiratory Syndrome-Associated Coronavirus (SARS-CoV) Nucleocapsid-Based Western Blot Assay Were Rectified by the Use of Two Subunits (S1 and S2) of Spike for Detection of Antibody to SARS-CoV

Mimoun Maache,1* Florence Komurian-Pradel,1 Alain Rajoharison,1 Magali Perret,1 Jean-Luc Berland,1 Stéphane Pouzol,1 Audrey Bagnaud,1 Blandine Duverger,1 Jianguo Xu,2 Antonio Osuna,3 and Glaucia Paranhos-Baccalà1

Emerging Pathogens Department of bioMérieux, IFR128 BioSciences Lyon Gerland, CERVI, 21, Avenue Tony Garnier, 69365 Lyon Cedex 07, France,1 State Key Laboratory for Infectious Disease Prevention and Control (China CDC), National Institute for Communicable Disease Control and Prevention, Changping, Beijing 100026, China,2 Biotechnology Institute, University of Granada, Cp 18071, Granada, Spain3

Received 20 September 2005/ Returned for modification 31 October 2005/ Accepted 27 December 2005

To evaluate the reactivity of the recombinant proteins expressed in Escherichia coli strain BL21(DE3), a Western blot assay was performed by using a panel of 78 serum samples obtained, respectively, from convalescent-phase patients infected with severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (30 samples) and from healthy donors (48 samples). As antigen for detection of SARS-CoV, the nucleocapsid protein (N) showed high sensitivity and strong reactivity with all samples from SARS-CoV patients and cross-reacted with all serum samples from healthy subjects, with either those obtained from China (10 samples) or those obtained from France (38 serum samples), giving then a significant rate of false positives. Specifically, our data indicated that the two subunits, S1 (residues 14 to 760) and S2 (residues 761 to 1190), resulted from the divided spike reacted with all samples from SARS-CoV patients and without any cross-reactivity with any of the healthy serum samples. Consequently, these data revealed the nonspecific nature of N protein in serodiagnosis of SARS-CoV compared with the S1 and S2, where the specificity is of 100%. Moreover, the reported results indicated that the use of one single protein as a detection antigen of SARS-CoV infection may lead to false-positive diagnosis. These may be rectified by using more than one protein for the serodiagnosis of SARS-CoV.

* Corresponding author. Mailing address: Emerging Pathogens Department of bioMérieux, CERVI, 21 Avenue Tony Garnier, 69365 cedex 07, Lyon, France. Phone: 33 04 37 28 24 13. Fax: 33 04 37 28 24 11. E-mail: mmaache{at}ugr.es.

Clinical and Vaccine Immunology, March 2006, p. 409-414, Vol. 13, No. 3
1071-412X/06/$08.00+0     doi:10.1128/CVI.13.3.409-414.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chan, C.-M., Woo, P. C. Y., Lau, S. K. P., Tse, H., Chen, H.-L., Li, F., Zheng, B.-J., Chen, L., Huang, J.-D., Yuen, K.-Y. (2008). Spike Protein, S, of Human Coronavirus HKU1: Role in Viral Life Cycle and Application in Antibody Detection. Exp Biol Med 233: 1527-1536 [Abstract] [Full Text]  
  • Vlasova, A. N., Zhang, X., Hasoksuz, M., Nagesha, H. S., Haynes, L. M., Fang, Y., Lu, S., Saif, L. J. (2007). Two-Way Antigenic Cross-Reactivity between Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Group 1 Animal CoVs Is Mediated through an Antigenic Site in the N-Terminal Region of the SARS-CoV Nucleoprotein. J. Virol. 81: 13365-13377 [Abstract] [Full Text]  
  • Haynes, L. M., Miao, C., Harcourt, J. L., Montgomery, J. M., Le, M. Q., Dryga, S. A., Kamrud, K. I., Rivers, B., Babcock, G. J., Oliver, J. B., Comer, J. A., Reynolds, M., Uyeki, T. M., Bausch, D., Ksiazek, T., Thomas, W., Alterson, H., Smith, J., Ambrosino, D. M., Anderson, L. J. (2007). Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins. CVI 14: 331-333 [Abstract] [Full Text]  
  • Yip, C. W., Hon, C. C., Zeng, F., Chow, K. Y. C., Chan, K. H., Peiris, J. S. M., Leung, F. C. C. (2007). Naturally Occurring Anti-Escherichia coli Protein Antibodies in the Sera of Healthy Humans Cause Analytical Interference in a Recombinant Nucleocapsid Protein-Based Enzyme-Linked Immunosorbent Assay for Serodiagnosis of Severe Acute Respiratory Syndrome. CVI 14: 99-101 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»